Drug intelligence / Profile preview

l-5-hydroxytryptophan + carbidopa + phentermine

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of l-5-hydroxytryptophan (5-HTP), carbidopa, and phentermine used for weight loss treatment. 5-HTP is a precursor to serotonin that increases brain serotonin levels when combined with carbidopa, which prevents peripheral conversion of 5-HTP to serotonin. Phentermine is an amphetamine derivative that suppresses appetite. This triple combination has been shown to produce greater weight loss with fewer psychomotor side effects than each drug alone.

Other names: 5-HTP + carbidopa + phenterminephentermine + 5-HTP/carbidopa

Targets

DDC (Aromatic L-amino acid decarboxylase)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on l-5-hydroxytryptophan + carbidopa + phentermine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-5-hydroxytryptophan + carbidopa + phentermine.

Explore the full profile